Traders Buy Large Volume of Call Options on Trevi Therapeutics (NASDAQ:TRVI)

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) was the recipient of some unusual options trading on Tuesday. Traders bought 5,103 call options on the company. This represents an increase of 802% compared to the typical daily volume of 566 call options.

Analyst Ratings Changes

TRVI has been the topic of a number of recent analyst reports. Oppenheimer increased their target price on Trevi Therapeutics from $12.00 to $20.00 and gave the company an "outperform" rating in a research report on Tuesday. Needham & Company LLC increased their price objective on shares of Trevi Therapeutics from $8.00 to $25.00 and gave the company a "buy" rating in a report on Monday. HC Wainwright upped their price target on shares of Trevi Therapeutics from $7.50 to $12.50 and gave the stock a "buy" rating in a research report on Monday. Raymond James upgraded Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and lifted their price objective for the stock from $9.00 to $29.00 in a report on Monday. Finally, D. Boral Capital restated a "buy" rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a report on Friday. Seven research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $15.94.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Summit Investment Advisors Inc. raised its stake in Trevi Therapeutics by 84.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock worth $26,000 after purchasing an additional 2,894 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Trevi Therapeutics by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company's stock worth $40,000 after buying an additional 6,764 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Trevi Therapeutics in the fourth quarter valued at approximately $49,000. Squarepoint Ops LLC acquired a new stake in Trevi Therapeutics during the fourth quarter worth $58,000. Finally, Intech Investment Management LLC purchased a new stake in Trevi Therapeutics in the 3rd quarter valued at about $63,000. Institutional investors and hedge funds own 95.76% of the company's stock.

Trevi Therapeutics Trading Up 0.5 %

NASDAQ TRVI traded up $0.03 on Tuesday, reaching $6.10. 1,062,088 shares of the company were exchanged, compared to its average volume of 1,970,479. Trevi Therapeutics has a fifty-two week low of $2.30 and a fifty-two week high of $7.39. The stock has a market capitalization of $468.88 million, a P/E ratio of -13.78 and a beta of 0.90. The business's fifty day moving average price is $4.18 and its 200 day moving average price is $3.54.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads